Benicar

This page contains recent news articles, when available, and an overview of Benicar but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Overview:

Benicar (when available)

Pharmacology and use:
Olmesartan Medoxomil, a specific angiotensin II antagonist, is used alone or with other antihypertensive agents to treat hypertension. Unlike the angiotensin receptor antagonist losartan, Olmesartan Medoxomil does not have an active metabolite or possess uricosuric effects. For the treatment of hypertension

Mechanism Of Action:
Olmesartan Medoxomil competes with angiotensin II for binding at the also stimulates the synthesis and release of aldosterone, blockage of its effects results in a decrease in systemic vascular resistance.

News Articles on Olmesartan Medoxomil

Daiichi Sankyo Falls Most on Record Ahead of Meeting (Update1)  -  Oct 7, 2008
Daiichi Sankyo, which sells the Benicar hypertension drug, and its partner Eli Lilly & Co. are awaiting US approval to sell the experimental blood thinner Bloomberg

Forest Labs Sees Generic Threat  -  Sep 25, 2008
Principal brands include Lexapro for depression, Namenda for Alzheimer's disease, and Benicar for high blood pressure. The company turned in a very strong Trading Markets (press release),

Senior Dimensions Lowers Prescription Drug Co-Payments on Many ...  -  Sep 24, 2008
The more widely used maintenance drugs with reduced co-pays include: Avapro and Benicar, both used to treat hypertension; Actos and Lantus, used to treat MarketWatch

Zacks Analyst Blog Highlights: Forest Laboratories, Inc., CarMax ...  -  Sep 25, 2008
Principal brands include Lexapro for depression, Namenda for Alzheimer's disease and Benicar for high blood pressure. Forest has a number of other PR-Inside.com (Pressemitteilung),

Zacks Analyst Blog Highlights: Forest Laboratories, Inc., CarMax ...  -  Sep 25, 2008
Principal brands include Lexapro for depression, Namenda for Alzheimer's disease and Benicar for high blood pressure. Forest has a number of other Business Wire (press release),

CV Therapeutics Announces License Agreement for Ranexa(R) in ...  15 Sep 2008
...sitagliptin (Januvia(R)), esomeprazole (Nexium(R)), fluticasone/salmeterol (Advair(R)), nebivolol (Nebilet(R)) and olmesartan (Benicar(R)).PipelineReview.com (press release),

CV Therapeutics Announces License Agreement for Ranexa(R) in ...  Sep 12, 2008
...sitagliptin (Januvia(R)), esomeprazole (Nexium(R)), fluticasone/salmeterol (Advair(R)), nebivolol (Nebilet(R)) and olmesartan (Benicar(R)).Earthtimes (press release),

Indian Institute Defends Conduct of Clinical Trials  Aug 28, 2008
Two of the industry-sponsored trials were for Daiichi Sankyo’s Benicar (olmesartan medoxomil) and Novartis’ Diovan (valsartan), both hypertension drugs.FDA news (subscription),

Drug industry jobs disappearing in NJ  Aug 24, 2008
Sales for Daiichi Sankyo, which makes the blood pressure medication Benicar, increased 16 percent between 2006 and 2007 to exceed $1 billion, Salem said.New Brunswick Home News Tribune,

Forest 1Q profit falls 9 percent on Azor charge  -  Jul 22, 2008
Revenue from Benicar, which Forest promotes with Daiichi Sankyo, came in at $52.4 million, about even with the first quarter of fiscal 2008. CNNMoney.com

New Study Shows Benicar(R) (olmesartan medoxomil) Reverses Blood ...  -  Jun 19, 2008
...(2) Olmesartan medoxomil is marketed in the United States by Daiichi Sankyo, Inc. as Benicar(R). Benicar and Benicar HCT (olmesartan HispanicBusiness.com (press release),

New Study Shows BENICAR(R) (olmesartan medoxomil) Reverses Blood ...  -  Jun 16, 2008
BENICAR and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) are indicated for the treatment of hypertension. They may be used alone or in PR Newswire (press release),

Daiichi bags 2 patents for hypertension drug  -  Jun 16, 2008
The patents are for a key hypertension drug that sells under brand names Benicar and Benicar HCT or Olmitec and is one of its biggest money spinners Business Standard,

Daiichi to pay up to $4.6 billion for control of Ranbaxy  -  Jun 11, 2008
Shares in Daiichi Sankyo, best known for its high blood pressure medication Benicar and the experimental blood thinner prasugrel, ended nearly 5 percent Reuters

Exploring the ins and outs of blood pressure treatment  -  Jun 16, 2008
Two examples are Benicar and Diovan. The newest blood pressure medicine, Tekturna, has not been demonstrated to be a factor in ED, but it's so new that SouthCoastToday.com,

Mesotec Moves HQ From Germany to Green Tree  -  Jun 6, 2008
Daiichi, based in Tokyo, has already sued Mylan over its plan to sell a copy of Benicar, claiming it would violate the 2016 patent. RedOrbit,

Popular Drugs, Side-Effects and Feeling Ill  -  Jul 1, 2008
...as well as the Designer Drugs; angiotensin II receptor blockers (ARBs); Olmesartan (Benicar ) including candesartan (Atacand) and irbesartan (Avapro), Rocklin and Roseville Today,

Blood Pressure Medications Can Multi-Task  -  Jun 30, 2008
A newer group of drugs –but similar in action- came out and these “ARBs�? are known as Cozaar, Diovan, Avapro, Atacand and Micardis and Benicar. Best of Times,

Hypertension Treatment Effective In Reversing Vascular Damage ...  -  Jun 22, 2008
Olmesartan medoxomil is marketed in the United States as Benicar® and in Europe as Olmetec® by Daiichi Sankyo, Inc., which funded the study. Science Daily (press release)

New Study Shows BENICAR(R) (Olmesartan Medoxomil) Reverses Blood ...  -  Jun 16, 2008
BENICAR and BENICAR HCT(R) (olmesartan medoxomil/hydrochlorothiazide) are indicated for the treatment of hypertension. They may be used alone or in RedOrbit,

Japan's Daiichi Sankyo in 4.6 bin dlr takeover of India's Ranbaxy  -  Jun 11, 2008
Daiichi Sankyo -- best known for its high blood pressure medication Benicar -- is seen by analysts as having a solid number of new drugs in its development AFP

Drug may reverse vascular damage  -  Jun 18, 2008
Olmesartan medoxomil is marketed in the United States as Benicar and in Europe as Olmetec by Daiichi Sankyo Inc., which funded the study. United Press International

Russian Roulette, Generic Buyout  -  Jun 11, 2008
Ranbaxy, one of India’s largest companies, is a leading maker of generic drugs worldwide; Daiichi is best known for its blood-pressure drug Benicar. The Week Daily

Forest ends promotion of Daiichi hypertension drug  -  May 13, 2008
N: Quote, Profile, Research) Norvasc and Daiichi's Benicar, had won US approval in September. The companies had earlier struck a deal to co-promote Benicar. Reuters

New Data Shows 45 Percent of Patients With Stage 1 Hypertension ...  -  May 14, 2008
Eight out of 10 (cumulative 81%) patients with stage 1 hypertension were able to reach a goal blood pressure (BP) of < 140/90 mm Hg on BENICAR and BENICAR Earthtimes (press release),

Daiichi Sankyo 4th-Quarter Profit Rises on Blood Pressure Drugs  -  May 12, 2008
Shares of Daiichi Sankyo, which makes Benicar blood pressure pills, fell as much as 6.5 percent to 2670 yen after the earnings were announced at 1 pm They Bloomberg

Pharmacopeia's First-in-Class Investigational Therapy PS433540 ...  -  May 16, 2008
...(1) Prescribing Information for Coreg CR(R), Lotensin(R), Avapro(R), Benicar(R) and Norvasc(R) (2) American Heart Association news release. PR Newswire (press release),

Many Possible Routes to the Goal of 120/80  -  Apr 21, 2008
They include Diovan, Benicar and Avapro. Calcium channel blockers. Drugs like Norvasc, Procardia XL and DynaCirc CR help dilate blood vessels by preventing New York Times,

Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter ...  -  Apr 15, 2008
Sales of Namenda increased 26% to $829657000 from $660295000 while the earnings contribution from the Benicar co-promotion increased 22% to $212100000 from PR Newswire (press release),

Forest Labs Guides for 2009 Below Street  -  Apr 15, 2008
However, the company's co-promotion deal with partner Daiichi Sankyo for Benicar has expired, and there will be a gradual reduction in profit percentage on Houston Chronicle,

Forest Lab Swings To Profit In Q4; Sees FY09 Results Below Street ...  -  Apr 15, 2008
The company also predicts nearly 4% revenue growth for the year that includes product sales as well as the earnings contribution from Benicar, RTT News,

Forest backs pipeline as Lexapro and Namenda climb again  -  Apr 16, 2008
The antihypertensive Benicar (olmesartan medoxomil), which is co-promoted with Japan’s Daiichi Sankyo, brought in $58.2 million, an increase of 27%. Pharma Times (subscription),

Posted By Dr. Peter Gott  -  Apr 7, 2008
He is on Zetia, Benicar, Lipitor, aspirin and Effexor. His problem is that when he lies on his left side, he hears a pulsating blood-flow noise in his right Northern Daily News,

Forest Laboratories, Inc. Reports Fiscal Year 2008 Fourth Quarter ...  -  Apr 15, 2008
...earnings contribution of $58232000 from the co-promotion of Benicar(R) (olmesartan medoxomil) and Benicar HCT(R), antihypertensive therapies, Biloxi Sun Herald,

Forest Laboratories, Inc. Announces Amendment to Bystolic(TM ...  -  Feb 28, 2008
Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and Benicar HCT are registered trademarks of Daiichi Sankyo, Inc.; and Campral is a registered FOXBusiness

Daiichi Sankyo Gains After Drug Gets Priority Review (Update6)  -  Feb 21, 2008
Daiichi jumped 4.2 percent as the Tokyo-based company moved closer to its first US release of an original drug since the Benicar blood-pressure pill in 2002 Bloomberg

Forest Laboratories, Inc. Announces Positive Results of Memantine ...  -  Feb 5, 2008
...*Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and Benicar HCT are registered trademarks of Daiichi Sankyo, Inc.; and Campral is a registered FOXBusiness

Under the Weather  -  Jan 31, 2008
Successful drugs include Benicar, a small-selling cholesterol drug called Welchol and a new blood pressure pill called Azor. And now comes perhaps the Forbes,

Forest Laboratories, Inc. Reports Q3'08 Diluted Earnings Per Share ...  -  Jan 15, 2008
Namenda sales exceeded $200 million for the first time, while Lexapro also generated record sales and income from the Benicar(R) co-promotion remained CNNMoney.com

Daiichi Sankyo Profit Triples on Sales of Blood Pressure Drugs  -  Jan 30, 2008
...or 107 yen a share, a year earlier, the maker of the Benicar hypertension medicine said in a statement to the Tokyo Stock Exchange. Bloomberg

Daiichi Sankyo Profit Rises on Blood Pressure Drugs (Update1)  -  Jan 30, 2008
31, from 77.7 billion yen, or 107 yen, a year earlier, the maker of the Benicar hypertension medicine said in a statement to the Tokyo Stock Exchange today. Bloomberg

Forest Raises 2008 Profit Outlook  -  Jan 15, 2008
Forest also said it will complete its co-promotion deal for the high blood pressure drug Benicar at the end of the fiscal year and will reallocate the sales Houston Chronicle,

Forest Laboratories 3Q net rises; Lexapro sales up  -  Jan 15, 2008
...from $250.3 million, or 78 cents a share, a year earlier, helped in part by the co-promotion of antihypertensive therapies Benicar and Benicar HCT. MarketWatch

Lexapro, Namenda Boost Outlook for Forest Labs  -  Jan 15, 2008
Sales of antihypertensive therapies Benicar and Benicar HCT, which it co-promotes with Japanese company Daiichi Sankyo Co. Ltd., grew 34% to $830.4 million. Wall Street Journal

Forest Labs Q3 Profit Up 21% On Strong Sales Of Lexapro And ...  -  Jan 15, 2008
Also included in the revenues were earnings contribution of $51.8 million from the co-promotion of Benicar and Benicar HCT, antihypertensive therapies, RTT News,

Novexel and Forest Laboratories Announce License Agreement for NXL ...  -  Jan 22, 2008
...*Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and Benicar HCT are registered trademarks of Daiichi Sankyo, Inc.; and Campral is a registered CNNMoney.com

Forest Labs 3Q Profit Up 20.6 Percent  -  Jan 15, 2008
Other income, which includes contract revenue from the high blood pressure drugs Benicar and Benicare HCT, totaled $80.1 million. Houston Chronicle,

Forest Labs profit rises due to depression and Alzheimer's drugs  -  Jan 15, 2008
Other products include Benicar and Campral. Benicar is used in the treatment of hypertension. Campral is for the maintenance of abstinence from alcohol in Pravda,

Forest Laboratories, Inc. Reports Q3'08 Diluted Earnings Per Share ...  -  Jan 15, 2008
...earnings contribution of $51753000 from the co-promotion of Benicar(R)* (olmesartan medoxomil) and Benicar HCT(R), antihypertensive therapies, Biloxi Sun Herald,

Forest Laboratories: Share price displays bullish "flag" formation  -  Jan 23, 2008
Offerings include Lexapro, for the treatment of depression, Namenda for Alzheimer's disease, Benicar for hypertension, and Campral for the maintenance of BloggingStocks

Lexapro and Namenda help Forest beat analyst estimates  -  Jan 16, 2008
The antihypertensive Benicar (olmesartan medoxomil), which is co-promoted with Japan’s Daiichi Sankyo, brought in $51.8 million, an increase of 34%. Pharma Times (subscription),

WRAPUP 1-Takeda and Daiichi profits up, Chugai shares tank  -  Jan 31, 2008
...formed when Sankyo bought Daiichi Pharmaceutical, posted a stronger climb in income on a jump in sales for its high blood pressure medicine Benicar. Reuters UK,

Takeda 9mth profit up 25 pct on strong Actos sales  -  Jan 30, 2008
...profit for the April-December period jumped, rising 24 percent to 96.4 billion yen, helped by strong sales of its high blood pressure medicine Benicar. Guardian Unlimited,

Forest's Third-Quarter Profit Increases on Drug Sales (Update4)  -  Jan 15, 2008
Revenue from the blood-pressure drug Benicar, which Forest co- promotes with Japan's Daiichi Sankyo Co., increased 34 percent to $51.8 million. Bloomberg

The Street Corner: Global Market Perspective vs. Forest ...  -  Feb 5, 2008
In addition to our growing product line, Forest also co-promotes the Daiichi Sankyo, Inc. products Benicar, an angiotensin receptor blocker; Benicar HCT, Trading Markets (press release),

UPDATE: Nebivolol Lowers Blood Pressure in African Americans With ...  -  Nov 1, 2007
Benicar is a registered trademark of Daiichi Sankyo, Inc., and Campral is a registered trademark of Merck Sante sas, subsidiary of Merck kgaa, Darmstadt, CNNMoney.com

Daaichi Sankyo profit falls on domestic sales  -  Nov 6, 2007
...in the current year as a weaker yen and stronger demand in Europe for its blood pressure drug Benicar buffer earnings from slumping domestic sales. International Herald Tribune,

Japan Drug Makers Sales Are Solid  -  Nov 6, 2007
...yen from 78.35 billion yen, thanks to cost cutting and growing sales of Daiichi Sankyo's blood-pressure drug Benicar and antibacterial agent Cravit. Wall Street Journal

Daiichi Sankyo hikes H1 outlook, nudges up full-yr  -  Oct 26, 2007
The Japanese drug maker, which is gearing up for a major US expansion, has been benefiting from robust US sales of its high blood pressure medicine Benicar Reuters

Milnacipran Demonstrated Significant Improvement in Pain and the ...  -  Nov 8, 2007
...*Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and Benicar HCT are registered trademarks of Daiichi Sankyo, Inc.; and Campral is a registered PharmaLive.com (press release),

Common Medications Provide Equal Blood Pressure Control  -  Nov 1, 2007
The arbs included were candesartan cilexetil (Atacand), eprosartan (Teveten), irbesartan (Avapro), losartan (Cozaar), olmesartan medoxomil (Benicar), Earthtimes,

Brand Names/Synonyms:
Benicar is also known by the following brand names and/or synonymsBenicar; CS 866; Olmesartan; Olmesartan Medoximil; Olmesartan Medoxomil; Olmetec

Drug Category:
Benicar is categorized under the following by the FDA: Antihypertensive Agents; ATC:C09CA08

Dosage Forms:
~13 hours

Absorption:
Bioavailability is about 26%

Interactions:
Drug Interactions for Olmesartan Medoxomil:

No significant drug interactions were reported in studies in which olmesartan medoxomil was co-administered with digoxin or warfarin in healthy volunteers. The bioavailability of olmesartan was not significantly altered by the co-administration of antacids [Al(OH)₃/Mg(OH)₂]. Olmesartan medoxomil is not metabolized by the cytochrome P450 system and has no effects on P450 enzymes; thus, interactions with drugs that inhibit, induce or are metabolized by those enzymes are not expected.

Chemical IUPAC Name:
(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl5-(1-hydroxy-1-methyl-ethyl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-3H-imidazole-4-carboxylate

:

Web health.mongabay.com

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.